Cargando…
Clinical significance of 206 station lymph node in transverse colon cancer
BACKGROUND: Lymph node (LN) metastasis is crucial in determining the prognosis and treatment options for colon cancer patients. Our work was to study whether the lymph nodes beyond D3 station in transverse colon cancer, especially 206 LN, should be dissected. METHODS: A total of 225 patients within...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189469/ https://www.ncbi.nlm.nih.gov/pubmed/35437894 http://dx.doi.org/10.1002/cam4.4626 |
_version_ | 1784725597069508608 |
---|---|
author | Xu, Yu Xin Huang, Ying Wang, Xiao Jie Ye, Dao Xiong Chi, Pan |
author_facet | Xu, Yu Xin Huang, Ying Wang, Xiao Jie Ye, Dao Xiong Chi, Pan |
author_sort | Xu, Yu Xin |
collection | PubMed |
description | BACKGROUND: Lymph node (LN) metastasis is crucial in determining the prognosis and treatment options for colon cancer patients. Our work was to study whether the lymph nodes beyond D3 station in transverse colon cancer, especially 206 LN, should be dissected. METHODS: A total of 225 patients within our department were reviewed. The primary and secondary endpoints were overall survival (OS) and disease‐free survival (DFS). We employed Propensity score weighting (PSW) for weighing participants to balance observed confounders between the 206(D+) group and the 206(D−) group. RESULTS: The rate of metastasis in station 206 was 9.3%. Only T stage (OR, 3.009; 95% CI, 1.018–8.892), N stage (OR, 9.818; 95% CI, 1.158–83.227), and M stage (OR, 26.126; 95% CI, 1.274–535.945) were an independent risk factor for 206 station metastasis in multivariate logistic analysis. The 206(D+) group had a similarly survival than the 206(D−) group (3‐year DFS, 89.6% v 85.9%; p = 0.389; 3‐year OS, 94.6% v 85.3% p = 0.989). PSW further verified it. Metastasis of 206 station LN is not an independent prognostic factor, but a predictive factor of DFS. CONCLUSION: Station 206 LN positive is a predictive factor for DFS. Only the patient with T1‐3, N+ who is at a high risk of 206 station LN metastases should consider dissecting 206 station LN. |
format | Online Article Text |
id | pubmed-9189469 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91894692022-06-16 Clinical significance of 206 station lymph node in transverse colon cancer Xu, Yu Xin Huang, Ying Wang, Xiao Jie Ye, Dao Xiong Chi, Pan Cancer Med RESEARCH ARTICLES BACKGROUND: Lymph node (LN) metastasis is crucial in determining the prognosis and treatment options for colon cancer patients. Our work was to study whether the lymph nodes beyond D3 station in transverse colon cancer, especially 206 LN, should be dissected. METHODS: A total of 225 patients within our department were reviewed. The primary and secondary endpoints were overall survival (OS) and disease‐free survival (DFS). We employed Propensity score weighting (PSW) for weighing participants to balance observed confounders between the 206(D+) group and the 206(D−) group. RESULTS: The rate of metastasis in station 206 was 9.3%. Only T stage (OR, 3.009; 95% CI, 1.018–8.892), N stage (OR, 9.818; 95% CI, 1.158–83.227), and M stage (OR, 26.126; 95% CI, 1.274–535.945) were an independent risk factor for 206 station metastasis in multivariate logistic analysis. The 206(D+) group had a similarly survival than the 206(D−) group (3‐year DFS, 89.6% v 85.9%; p = 0.389; 3‐year OS, 94.6% v 85.3% p = 0.989). PSW further verified it. Metastasis of 206 station LN is not an independent prognostic factor, but a predictive factor of DFS. CONCLUSION: Station 206 LN positive is a predictive factor for DFS. Only the patient with T1‐3, N+ who is at a high risk of 206 station LN metastases should consider dissecting 206 station LN. John Wiley and Sons Inc. 2022-04-18 /pmc/articles/PMC9189469/ /pubmed/35437894 http://dx.doi.org/10.1002/cam4.4626 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Xu, Yu Xin Huang, Ying Wang, Xiao Jie Ye, Dao Xiong Chi, Pan Clinical significance of 206 station lymph node in transverse colon cancer |
title | Clinical significance of 206 station lymph node in transverse colon cancer |
title_full | Clinical significance of 206 station lymph node in transverse colon cancer |
title_fullStr | Clinical significance of 206 station lymph node in transverse colon cancer |
title_full_unstemmed | Clinical significance of 206 station lymph node in transverse colon cancer |
title_short | Clinical significance of 206 station lymph node in transverse colon cancer |
title_sort | clinical significance of 206 station lymph node in transverse colon cancer |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189469/ https://www.ncbi.nlm.nih.gov/pubmed/35437894 http://dx.doi.org/10.1002/cam4.4626 |
work_keys_str_mv | AT xuyuxin clinicalsignificanceof206stationlymphnodeintransversecoloncancer AT huangying clinicalsignificanceof206stationlymphnodeintransversecoloncancer AT wangxiaojie clinicalsignificanceof206stationlymphnodeintransversecoloncancer AT yedaoxiong clinicalsignificanceof206stationlymphnodeintransversecoloncancer AT chipan clinicalsignificanceof206stationlymphnodeintransversecoloncancer |